Attrition is a significant methodological concern in longitudinal studies. Sample loss can limit generalizability and compromise internal validity. Wave one ( = 346) and wave two follow-ups ( = 196) of the 1Florida ADRC clinical core were examined using a 24-month visit window.
View Article and Find Full Text PDFNeuroimaging and biofluid biomarkers provide a proxy of pathological changes for Alzheimer's disease (AD) and are useful in improving diagnosis and assessing disease progression. However, it is not clear how race/ethnicity and different prevalence of AD risks impact biomarker levels. In this narrative review, we survey studies focusing on comparing biomarker differences between non-Hispanic White American(s) (NHW), African American(s) (AA), Hispanic/Latino American(s) (HLA), and Asian American(s) with normal cognition, mild cognitive impairment, and dementia.
View Article and Find Full Text PDFIntroduction: Commercially available plasma p-tau217 biomarker tests are not well studied in ethnically diverse samples.
Methods: We evaluated associations between ALZPath plasma p-tau217 and amyloid-beta positron emission tomography (Aβ-PET) in Hispanic/Latino (88% of Cuban or South American ancestry) and non-Hispanic/Latino older adults. One- and two-cutoff ranges were derived and evaluated to assess agreement with Aβ-PET.